Friday, April 03, 2026 8:54:12 AM
Isn’t it apparent there is a systematic attempt to see Anavex fail?
Is Mass Media correct in not following the progress Anavex has made towards a solution to Alzheimer’s? Is it a story that shouldn’t be told?
Or is it about Anavex wining the prize that awaits the first company to find a way to monetize the ailment universally? Isn’t the Media tied In with the power of Big Pharma, which seems to dominate the airwaves with one drug after another on every medium? Listening to the horrible side effects get rattled off by some of these drugs is chilling. All the while the patients are seen looking like Julie Andrews in the Sound of Music.
Martin Makary is aware of these distortions and is trying control the misrepresentations these behemoth corporations are perpetrating on the Public.
This is what Anavex is up against to get approval.
It’s possible Dr. M was naive in not carefully researching the possibility of approval with the EMA and mistakenly accepted their offer to apply for full approval. Then to see that wasn’t possible and tried to get whatever scrap that fell off the table, the add on to an existing therapy?
Aren’t the henchmen of Big Money, the Hedge Funds, complicit with Wall Street in starving every pre-revenue biotech in hopes of stealing the Intellectual Property, or forcing a sale for next to nothing? Or is the cast of the Off Broadway demolition crew that lingers on Message Boards really here to help us?
Now that Anavex is working with the New FDA team, they are closer than ever to seeing success. The hard press is on to remove Dr. Missling, to install some Wall Street flunky to somehow salvage or direct Anavex to some other end.
If a CPNV voucher or new trials aren’t forthcoming by early summer then some new Direction will be needed. But I don’t think a new CEO now will help get those things.
Happy Easter Dr. Missling, bring it home.
Is Mass Media correct in not following the progress Anavex has made towards a solution to Alzheimer’s? Is it a story that shouldn’t be told?
Or is it about Anavex wining the prize that awaits the first company to find a way to monetize the ailment universally? Isn’t the Media tied In with the power of Big Pharma, which seems to dominate the airwaves with one drug after another on every medium? Listening to the horrible side effects get rattled off by some of these drugs is chilling. All the while the patients are seen looking like Julie Andrews in the Sound of Music.
Martin Makary is aware of these distortions and is trying control the misrepresentations these behemoth corporations are perpetrating on the Public.
This is what Anavex is up against to get approval.
It’s possible Dr. M was naive in not carefully researching the possibility of approval with the EMA and mistakenly accepted their offer to apply for full approval. Then to see that wasn’t possible and tried to get whatever scrap that fell off the table, the add on to an existing therapy?
Aren’t the henchmen of Big Money, the Hedge Funds, complicit with Wall Street in starving every pre-revenue biotech in hopes of stealing the Intellectual Property, or forcing a sale for next to nothing? Or is the cast of the Off Broadway demolition crew that lingers on Message Boards really here to help us?
Now that Anavex is working with the New FDA team, they are closer than ever to seeing success. The hard press is on to remove Dr. Missling, to install some Wall Street flunky to somehow salvage or direct Anavex to some other end.
If a CPNV voucher or new trials aren’t forthcoming by early summer then some new Direction will be needed. But I don’t think a new CEO now will help get those things.
Happy Easter Dr. Missling, bring it home.
All my posts are my opinion only and shouldn’t be used for decisions regarding purchasing or selling.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
